there is no specific treatment for<unk> . The mainstay of treatment is supportive care. Standard infection control practices and proper barrier nursing techniques are recommended to avoid the spread of the infection from person to person. All suspected cases of<unk>  should be isolated. While tentative evidence supports the use of ribavirin, it has not yet been studied in people with the disease. Specific antibodies have also been studied in an animal model with potential benefit. Acyclovir, favipiravir, and remdesivir have been assessed as potential antivirals against<unk>  virus. M 102.4 is a nonpatented monoclonal antibody developed by Christopher C. Broder, a professor of immunology and microbiology at Uniformed Services University of the Health Sciences in Maryland. It proved highly effective in animal models. 50 doses were sent to Kerala in 2018, but it is not clear if they were used in humans. AChAdOx1 is vector based vaccination which is currently being tested on animals.
Nipah virus infection
Adenovirus infection
Living with COVID-19
Epstein–Barr virus infection
Spanish flu
Hong Kong flu
Marburg virus disease
Swine influenza